Plasma brain natriuretic peptide concentrations in patients with Kawasaki disease

Brain natriuretic peptide (BNP) is a cardiac hormone and plasma levels of it increase in patients with congestive heart failure and in those with acute myocardial infarction. Kawasaki disease (KD) is a well-known generalized vasculitis and the most prominent features of this disease are the cardiova...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Pediatrics international 2000-06, Vol.42 (3), p.241-248
Hauptverfasser: Kawamura, Takashi, Wago, Masakuni, Kawaguchi, Hiroshi, Yuge, Masahiro Tahara and Masako
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 248
container_issue 3
container_start_page 241
container_title Pediatrics international
container_volume 42
creator Kawamura, Takashi
Wago, Masakuni
Kawaguchi, Hiroshi
Yuge, Masahiro Tahara and Masako
description Brain natriuretic peptide (BNP) is a cardiac hormone and plasma levels of it increase in patients with congestive heart failure and in those with acute myocardial infarction. Kawasaki disease (KD) is a well-known generalized vasculitis and the most prominent features of this disease are the cardiovascular manifestations, which involve the pericardium, myocardium, endocardium and coronary arteries. It was hypothesized that the plasma concentrations of BNP in patients with KD might be increased and that plasma BNP might be a useful biological marker of cardiovascular manifestations in patients with KD. Blood was obtained to measure and compare plasma BNP concentrations in the acute (n = 32) and convalescent (n = 35) phases of KD and in the acute phase of the patients with viral infection (n = 26), which included adenovirus, influenza, measles and herpes group virus infection. In patients with KD, two-dimensional echocardiography was performed to check for pericardial effusion and coronary arterial lesions and to measure the dimensions of the left ventricle at diastole and the shortening fraction of the left ventricle (LVSF). The mean plasma BNP concentration in patients with KD in the acute phase was 55.0 +/- 39.5 pg/mL, but was 6.8 +/- 7.3 pg/mL in patients with viral infection. The plasma BNP concentration in patients with KD in the acute phase was significantly higher than in patients with viral infection (P < 0.0001). In 31 cases of KD, the plasma BNP concentrations were measured both in the acute and convalescent phases. The mean plasma BNP concentration in the acute phase of KD was 55.3 +/- 40.1 pg/mL and in the convalescent phase was 5.9 +/- 5.7 pg/mL. The level of plasma BNP decreased significantly in the convalescent phase (P < 0.0001). The mean BNP level in patients with KD with pericardial effusion (n = 8) in the acute phase was 80.3 +/- 43.4 pg/mL and that in patients without pericardial effusion (n = 24) was 46.5 +/- 35.1 pg/mL. The BNP level in patients with pericardial effusion was significantly higher than that of patients without pericardial effusion (P < 0.05). There was no significant correlation between the plasma concentrations of BNP in the acute phase of KD and LVSF (r = -0.161, P = 0.39, n = 31). It was shown that the plasma BNP concentration increased in the acute phase of KD and decreased to within normal range in the convalescent phase. Further examinations are needed to clarify the mechanism by which the elevated levels of plasma
doi_str_mv 10.1046/j.1442-200x.2000.01225.x
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_71230789</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>71230789</sourcerecordid><originalsourceid>FETCH-LOGICAL-c378t-9c6e44920a8b930623eb761f3c7bc1b6b434a0678b4f94a5e4e22c12caced1ee3</originalsourceid><addsrcrecordid>eNpNkEtP4zAQgC0EWl77F5BPe0vwK7FzRBWUR1kWCQQ3a-JOhUubBNsV3X-PS1m0l5mR55vx6COEclZypurTecmVEoVgbF3mwErGhajK9Q45-Nd43s21FKYwrNb75DDGeQaNNuoH2efMGF7p5oDc_1lAXAJtA_iOdpCCXwVM3tEBh-SnSF3fOexSgOT7LtJMDbnML5G--_RCb-AdIrx6OvURIeIx2ZvBIuLPr3xEHi_OH0aXxeRufDU6mxROapOKxtWoVCMYmLaRrBYSW13zmXS6dbytWyUV5NNNq2aNggoVCuG4cOBwyhHlEfm13TuE_m2FMdmljw4XC-iwX0WruZBMmyaDZgu60McYcGaH4JcQ_lrO7EannduNNbvRuQnMfuq06zx68vXHql3i9L_Brb8MFFvAx4Tr7z6EV1trqSv79Htsq-vR5f3tZGyN_ADxMoJx</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>71230789</pqid></control><display><type>article</type><title>Plasma brain natriuretic peptide concentrations in patients with Kawasaki disease</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Kawamura, Takashi ; Wago, Masakuni ; Kawaguchi, Hiroshi ; Yuge, Masahiro Tahara and Masako</creator><creatorcontrib>Kawamura, Takashi ; Wago, Masakuni ; Kawaguchi, Hiroshi ; Yuge, Masahiro Tahara and Masako</creatorcontrib><description>Brain natriuretic peptide (BNP) is a cardiac hormone and plasma levels of it increase in patients with congestive heart failure and in those with acute myocardial infarction. Kawasaki disease (KD) is a well-known generalized vasculitis and the most prominent features of this disease are the cardiovascular manifestations, which involve the pericardium, myocardium, endocardium and coronary arteries. It was hypothesized that the plasma concentrations of BNP in patients with KD might be increased and that plasma BNP might be a useful biological marker of cardiovascular manifestations in patients with KD. Blood was obtained to measure and compare plasma BNP concentrations in the acute (n = 32) and convalescent (n = 35) phases of KD and in the acute phase of the patients with viral infection (n = 26), which included adenovirus, influenza, measles and herpes group virus infection. In patients with KD, two-dimensional echocardiography was performed to check for pericardial effusion and coronary arterial lesions and to measure the dimensions of the left ventricle at diastole and the shortening fraction of the left ventricle (LVSF). The mean plasma BNP concentration in patients with KD in the acute phase was 55.0 +/- 39.5 pg/mL, but was 6.8 +/- 7.3 pg/mL in patients with viral infection. The plasma BNP concentration in patients with KD in the acute phase was significantly higher than in patients with viral infection (P &lt; 0.0001). In 31 cases of KD, the plasma BNP concentrations were measured both in the acute and convalescent phases. The mean plasma BNP concentration in the acute phase of KD was 55.3 +/- 40.1 pg/mL and in the convalescent phase was 5.9 +/- 5.7 pg/mL. The level of plasma BNP decreased significantly in the convalescent phase (P &lt; 0.0001). The mean BNP level in patients with KD with pericardial effusion (n = 8) in the acute phase was 80.3 +/- 43.4 pg/mL and that in patients without pericardial effusion (n = 24) was 46.5 +/- 35.1 pg/mL. The BNP level in patients with pericardial effusion was significantly higher than that of patients without pericardial effusion (P &lt; 0.05). There was no significant correlation between the plasma concentrations of BNP in the acute phase of KD and LVSF (r = -0.161, P = 0.39, n = 31). It was shown that the plasma BNP concentration increased in the acute phase of KD and decreased to within normal range in the convalescent phase. Further examinations are needed to clarify the mechanism by which the elevated levels of plasma BNP occur in the acute phase of KD. However, plasma BNP might be a useful biological marker of the cardiovascular manifestations in patients with KD.</description><identifier>ISSN: 1328-8067</identifier><identifier>EISSN: 1442-200X</identifier><identifier>DOI: 10.1046/j.1442-200x.2000.01225.x</identifier><identifier>PMID: 10881579</identifier><language>eng</language><publisher>Melbourne, Australia: Blackwell Science Pty</publisher><subject>Acute Disease ; Biomarkers - blood ; brain natriuretic peptide ; Chi-Square Distribution ; Child ; Child, Preschool ; Female ; Humans ; Infant ; Kawasaki disease ; Male ; Mucocutaneous Lymph Node Syndrome - blood ; Mucocutaneous Lymph Node Syndrome - physiopathology ; Natriuretic Peptide, Brain - blood ; Time Factors ; Virus Diseases - blood</subject><ispartof>Pediatrics international, 2000-06, Vol.42 (3), p.241-248</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c378t-9c6e44920a8b930623eb761f3c7bc1b6b434a0678b4f94a5e4e22c12caced1ee3</citedby><cites>FETCH-LOGICAL-c378t-9c6e44920a8b930623eb761f3c7bc1b6b434a0678b4f94a5e4e22c12caced1ee3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/10881579$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kawamura, Takashi</creatorcontrib><creatorcontrib>Wago, Masakuni</creatorcontrib><creatorcontrib>Kawaguchi, Hiroshi</creatorcontrib><creatorcontrib>Yuge, Masahiro Tahara and Masako</creatorcontrib><title>Plasma brain natriuretic peptide concentrations in patients with Kawasaki disease</title><title>Pediatrics international</title><addtitle>Pediatr Int</addtitle><description>Brain natriuretic peptide (BNP) is a cardiac hormone and plasma levels of it increase in patients with congestive heart failure and in those with acute myocardial infarction. Kawasaki disease (KD) is a well-known generalized vasculitis and the most prominent features of this disease are the cardiovascular manifestations, which involve the pericardium, myocardium, endocardium and coronary arteries. It was hypothesized that the plasma concentrations of BNP in patients with KD might be increased and that plasma BNP might be a useful biological marker of cardiovascular manifestations in patients with KD. Blood was obtained to measure and compare plasma BNP concentrations in the acute (n = 32) and convalescent (n = 35) phases of KD and in the acute phase of the patients with viral infection (n = 26), which included adenovirus, influenza, measles and herpes group virus infection. In patients with KD, two-dimensional echocardiography was performed to check for pericardial effusion and coronary arterial lesions and to measure the dimensions of the left ventricle at diastole and the shortening fraction of the left ventricle (LVSF). The mean plasma BNP concentration in patients with KD in the acute phase was 55.0 +/- 39.5 pg/mL, but was 6.8 +/- 7.3 pg/mL in patients with viral infection. The plasma BNP concentration in patients with KD in the acute phase was significantly higher than in patients with viral infection (P &lt; 0.0001). In 31 cases of KD, the plasma BNP concentrations were measured both in the acute and convalescent phases. The mean plasma BNP concentration in the acute phase of KD was 55.3 +/- 40.1 pg/mL and in the convalescent phase was 5.9 +/- 5.7 pg/mL. The level of plasma BNP decreased significantly in the convalescent phase (P &lt; 0.0001). The mean BNP level in patients with KD with pericardial effusion (n = 8) in the acute phase was 80.3 +/- 43.4 pg/mL and that in patients without pericardial effusion (n = 24) was 46.5 +/- 35.1 pg/mL. The BNP level in patients with pericardial effusion was significantly higher than that of patients without pericardial effusion (P &lt; 0.05). There was no significant correlation between the plasma concentrations of BNP in the acute phase of KD and LVSF (r = -0.161, P = 0.39, n = 31). It was shown that the plasma BNP concentration increased in the acute phase of KD and decreased to within normal range in the convalescent phase. Further examinations are needed to clarify the mechanism by which the elevated levels of plasma BNP occur in the acute phase of KD. However, plasma BNP might be a useful biological marker of the cardiovascular manifestations in patients with KD.</description><subject>Acute Disease</subject><subject>Biomarkers - blood</subject><subject>brain natriuretic peptide</subject><subject>Chi-Square Distribution</subject><subject>Child</subject><subject>Child, Preschool</subject><subject>Female</subject><subject>Humans</subject><subject>Infant</subject><subject>Kawasaki disease</subject><subject>Male</subject><subject>Mucocutaneous Lymph Node Syndrome - blood</subject><subject>Mucocutaneous Lymph Node Syndrome - physiopathology</subject><subject>Natriuretic Peptide, Brain - blood</subject><subject>Time Factors</subject><subject>Virus Diseases - blood</subject><issn>1328-8067</issn><issn>1442-200X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2000</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpNkEtP4zAQgC0EWl77F5BPe0vwK7FzRBWUR1kWCQQ3a-JOhUubBNsV3X-PS1m0l5mR55vx6COEclZypurTecmVEoVgbF3mwErGhajK9Q45-Nd43s21FKYwrNb75DDGeQaNNuoH2efMGF7p5oDc_1lAXAJtA_iOdpCCXwVM3tEBh-SnSF3fOexSgOT7LtJMDbnML5G--_RCb-AdIrx6OvURIeIx2ZvBIuLPr3xEHi_OH0aXxeRufDU6mxROapOKxtWoVCMYmLaRrBYSW13zmXS6dbytWyUV5NNNq2aNggoVCuG4cOBwyhHlEfm13TuE_m2FMdmljw4XC-iwX0WruZBMmyaDZgu60McYcGaH4JcQ_lrO7EannduNNbvRuQnMfuq06zx68vXHql3i9L_Brb8MFFvAx4Tr7z6EV1trqSv79Htsq-vR5f3tZGyN_ADxMoJx</recordid><startdate>20000601</startdate><enddate>20000601</enddate><creator>Kawamura, Takashi</creator><creator>Wago, Masakuni</creator><creator>Kawaguchi, Hiroshi</creator><creator>Yuge, Masahiro Tahara and Masako</creator><general>Blackwell Science Pty</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20000601</creationdate><title>Plasma brain natriuretic peptide concentrations in patients with Kawasaki disease</title><author>Kawamura, Takashi ; Wago, Masakuni ; Kawaguchi, Hiroshi ; Yuge, Masahiro Tahara and Masako</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c378t-9c6e44920a8b930623eb761f3c7bc1b6b434a0678b4f94a5e4e22c12caced1ee3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2000</creationdate><topic>Acute Disease</topic><topic>Biomarkers - blood</topic><topic>brain natriuretic peptide</topic><topic>Chi-Square Distribution</topic><topic>Child</topic><topic>Child, Preschool</topic><topic>Female</topic><topic>Humans</topic><topic>Infant</topic><topic>Kawasaki disease</topic><topic>Male</topic><topic>Mucocutaneous Lymph Node Syndrome - blood</topic><topic>Mucocutaneous Lymph Node Syndrome - physiopathology</topic><topic>Natriuretic Peptide, Brain - blood</topic><topic>Time Factors</topic><topic>Virus Diseases - blood</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kawamura, Takashi</creatorcontrib><creatorcontrib>Wago, Masakuni</creatorcontrib><creatorcontrib>Kawaguchi, Hiroshi</creatorcontrib><creatorcontrib>Yuge, Masahiro Tahara and Masako</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Pediatrics international</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kawamura, Takashi</au><au>Wago, Masakuni</au><au>Kawaguchi, Hiroshi</au><au>Yuge, Masahiro Tahara and Masako</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Plasma brain natriuretic peptide concentrations in patients with Kawasaki disease</atitle><jtitle>Pediatrics international</jtitle><addtitle>Pediatr Int</addtitle><date>2000-06-01</date><risdate>2000</risdate><volume>42</volume><issue>3</issue><spage>241</spage><epage>248</epage><pages>241-248</pages><issn>1328-8067</issn><eissn>1442-200X</eissn><abstract>Brain natriuretic peptide (BNP) is a cardiac hormone and plasma levels of it increase in patients with congestive heart failure and in those with acute myocardial infarction. Kawasaki disease (KD) is a well-known generalized vasculitis and the most prominent features of this disease are the cardiovascular manifestations, which involve the pericardium, myocardium, endocardium and coronary arteries. It was hypothesized that the plasma concentrations of BNP in patients with KD might be increased and that plasma BNP might be a useful biological marker of cardiovascular manifestations in patients with KD. Blood was obtained to measure and compare plasma BNP concentrations in the acute (n = 32) and convalescent (n = 35) phases of KD and in the acute phase of the patients with viral infection (n = 26), which included adenovirus, influenza, measles and herpes group virus infection. In patients with KD, two-dimensional echocardiography was performed to check for pericardial effusion and coronary arterial lesions and to measure the dimensions of the left ventricle at diastole and the shortening fraction of the left ventricle (LVSF). The mean plasma BNP concentration in patients with KD in the acute phase was 55.0 +/- 39.5 pg/mL, but was 6.8 +/- 7.3 pg/mL in patients with viral infection. The plasma BNP concentration in patients with KD in the acute phase was significantly higher than in patients with viral infection (P &lt; 0.0001). In 31 cases of KD, the plasma BNP concentrations were measured both in the acute and convalescent phases. The mean plasma BNP concentration in the acute phase of KD was 55.3 +/- 40.1 pg/mL and in the convalescent phase was 5.9 +/- 5.7 pg/mL. The level of plasma BNP decreased significantly in the convalescent phase (P &lt; 0.0001). The mean BNP level in patients with KD with pericardial effusion (n = 8) in the acute phase was 80.3 +/- 43.4 pg/mL and that in patients without pericardial effusion (n = 24) was 46.5 +/- 35.1 pg/mL. The BNP level in patients with pericardial effusion was significantly higher than that of patients without pericardial effusion (P &lt; 0.05). There was no significant correlation between the plasma concentrations of BNP in the acute phase of KD and LVSF (r = -0.161, P = 0.39, n = 31). It was shown that the plasma BNP concentration increased in the acute phase of KD and decreased to within normal range in the convalescent phase. Further examinations are needed to clarify the mechanism by which the elevated levels of plasma BNP occur in the acute phase of KD. However, plasma BNP might be a useful biological marker of the cardiovascular manifestations in patients with KD.</abstract><cop>Melbourne, Australia</cop><pub>Blackwell Science Pty</pub><pmid>10881579</pmid><doi>10.1046/j.1442-200x.2000.01225.x</doi><tpages>8</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1328-8067
ispartof Pediatrics international, 2000-06, Vol.42 (3), p.241-248
issn 1328-8067
1442-200X
language eng
recordid cdi_proquest_miscellaneous_71230789
source MEDLINE; Wiley Online Library Journals Frontfile Complete
subjects Acute Disease
Biomarkers - blood
brain natriuretic peptide
Chi-Square Distribution
Child
Child, Preschool
Female
Humans
Infant
Kawasaki disease
Male
Mucocutaneous Lymph Node Syndrome - blood
Mucocutaneous Lymph Node Syndrome - physiopathology
Natriuretic Peptide, Brain - blood
Time Factors
Virus Diseases - blood
title Plasma brain natriuretic peptide concentrations in patients with Kawasaki disease
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T13%3A07%3A58IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Plasma%20brain%20natriuretic%20peptide%20concentrations%20in%20patients%20with%20Kawasaki%20disease&rft.jtitle=Pediatrics%20international&rft.au=Kawamura,%20Takashi&rft.date=2000-06-01&rft.volume=42&rft.issue=3&rft.spage=241&rft.epage=248&rft.pages=241-248&rft.issn=1328-8067&rft.eissn=1442-200X&rft_id=info:doi/10.1046/j.1442-200x.2000.01225.x&rft_dat=%3Cproquest_cross%3E71230789%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=71230789&rft_id=info:pmid/10881579&rfr_iscdi=true